Patients initiating SGLT2i early were younger, and less likely to be female and have dyslipidemia, hypertension, concurrent use of insulin, lipid lowering, antiplatelet, or oral hypoglycemic therapy, and more likely to have a shorter duration of T2D (Table 1). This evidence concerns the gene INS and type 2 diabetes mellitus.